A new three-drug combination therapy significantly extended survival for patients with metastatic colorectal cancer and the BRAF V600E mutation, doubling life expectancy in a late-stage trial. CU Cancer Center’s Christopher Lieu, MD, a national leader in GI oncology, called the findings “very impactful,” stating the treatment now represents the new standard of care.